Cargando…

Role of intracellular tyrosines in activating KIT induced myeloproliferative disease

Gain-of-function mutations in KIT receptor in humans are associated with gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM), and acute myelogenous leukemia (AML). The intracellular signals that contribute to oncogenic KIT induced myeloproliferative disease (MPD) are poorly understood...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Peilin, Mali, Raghuveer Singh, Martin, Holly, Ramdas, Baskar, Sims, Emily, Kapur, Reuben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378686/ https://www.ncbi.nlm.nih.gov/pubmed/22297723 http://dx.doi.org/10.1038/leu.2012.22

Ejemplares similares

Targeting Rho Associated Kinases in Leukemia and Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Class I(A) PI3Kinase Regulatory Subunit, p85α, Mediates Mast Cell Development through Regulation of Growth and Survival Related Genes
por: Krishnan, Subha, et al.
Publicado: (2012)

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder
por: Chatterjee, Anindya, et al.
Publicado: (2015)

Unique and redundant roles of class I(A) PI3Kinase regulatory subunits in mast cell development
por: Mali, Raghuveer Singh, et al.
Publicado: (2013)

Driver Mutations in Leukemia Promote Disease Pathogenesis through a Combination of Cell-Autonomous and Niche Modulation
por: Ramdas, Baskar, et al.
Publicado: (2020)

ROCK1 via LIM kinase regulates growth, maturation and actin based functions in mast cells
por: Kapur, Reuben, et al.
Publicado: (2016)

Combined heterozygosity of FLT3(ITD), TET2, and DNMT3A results in aggressive leukemia
por: Ramdas, Baskar, et al.
Publicado: (2022)

Role of p85α in neutrophil extra- and intracellular reactive oxygen species generation
por: Li, Xing Jun, et al.
Publicado: (2016)

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms
por: Pandey, Ruchi, et al.
Publicado: (2015)

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
por: Pinilla-Ibarz, Javier, et al.
Publicado: (2016)

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
por: Richine, Briana M., et al.
Publicado: (2016)

Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms
por: Yu, Chunjie, et al.
Publicado: (2016)

Receptor tyrosine kinase C-kit promotes a destructive phenotype of FLS in osteoarthritis via intracellular EMT signaling
por: Cao, Xu, et al.
Publicado: (2023)

The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Hematopoietic Progenitor Hyperproliferation and Malignant Disease In Vivo
por: Nabinger, Sarah C., et al.
Publicado: (2012)

Physioxia-induced downregulation of Tet2 in hematopoietic stem cells contributes to enhanced self-renewal
por: Aljoufi, Arafat, et al.
Publicado: (2022)

Role and significance of c-KIT receptor tyrosine kinase in cancer: A review
por: Sheikh, Emana, et al.
Publicado: (2022)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Rapid development of myeloproliferative neoplasm in mice with Ptpn11(D61Y) mutation and haploinsufficient for Dnmt3a
por: Deng, Lisa, et al.
Publicado: (2017)

The spleen microenvironment influences disease transformation in a mouse model of KIT(D816V)-dependent myeloproliferative neoplasm
por: Pelusi, Natalie, et al.
Publicado: (2017)

Unveiling the Intracellular Survival Gene Kit of Trypanosomatid Parasites
por: Bartholomeu, Daniella Castanheira, et al.
Publicado: (2014)

Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice
por: Sharma, Namit, et al.
Publicado: (2014)

The Tyrosine Kinase-Driven Networks of Novel Long Non-coding RNAs and Their Molecular Targets in Myeloproliferative Neoplasms
por: Wong, Nonthaphat Kent, et al.
Publicado: (2021)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia
por: Havelange, Violaine, et al.
Publicado: (2013)

The Role of MicroRNAs in Myeloproliferative Neoplasia
por: Alizadeh, Shaban, et al.
Publicado: (2016)

The Role of New Technologies in Myeloproliferative Neoplasms
por: Palumbo, Giuseppe A., et al.
Publicado: (2019)

The Role of Inflammation and Inflammasome in Myeloproliferative Disease
por: Longhitano, Lucia, et al.
Publicado: (2020)

Allosteric Communication across the Native and Mutated KIT Receptor Tyrosine Kinase
por: Laine, Elodie, et al.
Publicado: (2012)

Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently
por: Zhang, Shaoting, et al.
Publicado: (2021)

Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations
por: Sandoval-Pérez, Angélica, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket
por: D'allard, Diane, et al.
Publicado: (2013)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
por: Geyer, Holly L., et al.
Publicado: (2015)

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1
por: Tefferi, Ayalew
Publicado: (2009)

DPP4 Truncated GM-CSF & IL-3 Manifest Distinct Receptor Binding & Regulatory Functions Compared to their Full Length Forms
por: O’Leary, Heather Ann, et al.
Publicado: (2017)

Targeting Bim via a lncRNA Morrbid Regulates the Survival of Preleukemic and Leukemic Cells
por: Cai, Zhigang, et al.
Publicado: (2020)

Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors
por: Puputti, Marjut, et al.
Publicado: (2009)

The Inherent Coupling of Intrinsically Disordered Regions in the Multidomain Receptor Tyrosine Kinase KIT
por: Ledoux, Julie, et al.
Publicado: (2022)

Correction to “Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations”
por: Sandoval-Pérez, Angélica, et al.
Publicado: (2022)

Mechanism of immune escape mediated by receptor tyrosine kinase KIT in thyroid cancer
por: Luo, Zhen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rf8vbc827fggp5dppjc5sa3kji